|
IFT52 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.18254320067035E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.51230028500038E-10 |
| Normal-vs-Stage2 |
1.80390000004138E-06 |
| Normal-vs-Stage3 |
2.20400031558654E-10 |
| Normal-vs-Stage4 |
5.41711120405353E-12 |
| Stage1-vs-Stage2 |
8.955200E-01 |
| Stage1-vs-Stage3 |
2.546600E-01 |
| Stage1-vs-Stage4 |
1.095640E-02 |
| Stage2-vs-Stage3 |
5.365400E-01 |
| Stage2-vs-Stage4 |
1.203610E-01 |
| Stage3-vs-Stage4 |
2.008800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.09783318389145E-13 |
| Normal-vs-AfricanAmerican |
1.001560E-03 |
| Normal-vs-Asian |
1.25350000046431E-07 |
| Caucasian-vs-AfricanAmerican |
3.191800E-01 |
| Caucasian-vs-Asian |
7.885400E-01 |
| AfricanAmerican-vs-Asian |
5.085600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.96159977150501E-10 |
| Normal-vs-Female |
1.72929448538639E-11 |
| Male-vs-Female |
5.875600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.82370005155741E-09 |
| Normal-vs-Age(41-60Yrs) |
2.40710007481937E-10 |
| Normal-vs-Age(61-80Yrs) |
3.11339842795633E-11 |
| Normal-vs-Age(81-100Yrs) |
7.025400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.373000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.133960E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.230600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.645200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.965400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.333800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.714300E-02 |
| Classical-VS-Follicular |
3.227200E-01 |
| Classical-VS-Other |
9.037000E-01 |
| Classical-VS-Normal |
5.60480550859666E-11 |
| Tall-VS-Follicular |
4.340000E-01 |
| Tall-VS-Other |
5.079600E-01 |
| Tall-VS-Normal |
2.96359999873985E-08 |
| Follicular-VS-Other |
8.325600E-01 |
| Follicular-VS-Normal |
8.43209999601413E-08 |
| Other-VS-Normal |
1.476110E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.47709996748347E-10 |
| Normal-vs-N1 |
1.33659971979228E-10 |
| N0-vs-N1 |
7.596300E-02 |
|
|
